Keryx Biopharmaceuticals Inc. (NASDAQ:KERX)’s share price dropped 1.1% during mid-day trading on Friday . The company traded as low as $7.34 and last traded at $7.43, with a volume of 407,661 shares. The stock had previously closed at $7.51.

KERX has been the topic of a number of research reports. Maxim Group reissued a “buy” rating and issued a $7.00 price objective (up previously from $5.00) on shares of Keryx Biopharmaceuticals in a report on Tuesday, March 29th. Cowen and Company reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a report on Monday, March 28th. BTIG Research reaffirmed a “sell” rating and set a $2.50 price target on shares of Keryx Biopharmaceuticals in a report on Tuesday, March 29th. FBR & Co lifted their price target on shares of Keryx Biopharmaceuticals from $10.00 to $13.00 and gave the company an “outperform” rating in a report on Wednesday, March 30th. Finally, Zacks Investment Research downgraded shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, April 27th. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and eight have given a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and a consensus price target of $8.84.

The firm’s market cap is $785.18 million. The firm has a 50 day moving average of $6.56 and a 200 day moving average of $5.06.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings results on Thursday, April 28th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. The company had revenue of $6.80 million for the quarter, compared to the consensus estimate of $6.63 million. The company’s revenue for the quarter was up 466.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.28) EPS. On average, equities analysts forecast that Keryx Biopharmaceuticals Inc. will post ($0.97) EPS for the current fiscal year.

An institutional investor recently bought a new position in Keryx Biopharmaceuticals stock. Royce & Associates LLC bought a new position in shares of Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 341,725 shares of the biopharmaceutical company’s stock, valued at approximately $1,726,000. Royce & Associates LLC owned 0.32% of Keryx Biopharmaceuticals at the end of the most recent quarter.

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron-based compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.